The Early Detection Research Network Biomarker Resource Laboratory at UCLA

加州大学洛杉矶分校早期检测研究网络生物标志物资源实验室

• 批准号: 7983045
• 负责人: DAVID S. CHIA
• 金额: $ 39.27万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-05-16 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7983045
• 关键词: Biological Assay; Biological Markers; Breast; Categories; Chromosome abnormality; Clinical; Collaborations; Comprehensive Cancer Center; DNA Modification Process; Data; Detection; Development; Diagnosis; Diagnostic; Disease Outcome; Early Detection Research Network; Estrogen Receptors; Estrogens; Funding; Goals; Grant; Histopathology; Human; Human Resources; Image; In Vitro; Individual; Laboratories; Leadership; Liquid substance; Lung; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Metabolism; Mission; Molecular Profiling; Mutation; Nature; Nucleic Acids; Pathway interactions; Patient Agents; Patients; Performance; Positron-Emission Tomography; Prostate; Proteins; Reagent; Reproduction spores; Research Infrastructure; Research Personnel; Resource Sharing; Resources; Risk Assessment; Staging; Stem cells; Stratification; Subgroup; Surface; Techniques; Technology; Testing; Time; Tissue Microarray; Tissues; Translating; Tumor Markers; cost; data mining; density; design; experience; flexibility; in vivo; malignant breast neoplasm; medical schools; meetings; member; novel; novel strategies; population based; pre-clinical; prognostic; programs; protein expression; stem; success; tool; tumor

DESCRIPTION (provided by applicant): The UCLA Biomarker Reference Laboratory (UCLA BRL) is designed to be a continuation and expansion of the established EDRN-funded UCLA BRL. Significantly, the UCLA BRL has been highly successful having established numerous EDRN collaborations and constructed and successfully utilized tissue microarray resources for EDRN investigators. Our goals are in close alignment with the mission of the EDRN and include: i) the utilization of our diverse and extensive infrastructure and highly skilled personnel to test, evaluate, quantify, validate and optimize detection of biomarkers useful early stage tumor marker. To this end, we have established Scientific Centers that can test for biomarkers which are protein and/or nucleic acid in nature in tissue and/or in fluids. To this end, the Scientific Centers have extensive experience and expertise in assay performance and development for tissues (full tissue sections or 'intelligent high-density tissue microarrays), proteins (including conventional and high-throughput protemics), and nucleic acids (including expression profiles, DNA modifications or mutations, chromosomal abnormalities, and/or microRNA profiles), ii) This includes a developmental program focused on defining clinically useful tumor markers utilizing high density tissue microarray combined with a novel data-mining tool suite, iii) The continuation of a program at UCLA that is highly professional and focused, yet at the same time flexible and cost-effective in order to meet the challenges of an evolving EDRN program, iv) A strong commitment to collaboration, teamwork, and sharing of resources and data with EDRN members in order to promote the goal of identifying clinically useful tumor biomarkers. The UCLA BRL leadership is highly capable and enthusiastic, and strongly dedicated to the goals of the EDRN. Moreover, the UCLA-BRL has strong institutional support from the School of Medicine, Jonsson Comprehensive Cancer Center, the UCLA Lung Cancer Program, and the UCLA Prostate Cancer SPORE.

描述（由申请人提供）：UCLA生物标志物参考实验室（UCLA BRL）旨在延续和扩展已建立的EDRN资助的UCLA BRL。值得注意的是，UCLA BRL已经建立了许多EDRN合作，并为EDRN研究人员建立了并成功利用组织微阵列资源。我们的目标与EDRN的使命保持一致，其中包括：i）利用我们多样化和广泛的基础设施以及高技能的人员来测试，评估，量化，量化，验证和优化生物标志物的检测有用的早期肿瘤标记物。为此，我们建立了科学中心，可以测试组织和/或流体中自然界中蛋白质和/或核酸的生物标志物。为此，科学中心在组织的性能和开发方面具有丰富的经验和专业知识（完整的组织部分或智能的高密度组织微阵列），蛋白质（包括常规和高通量原料），以及核酸（包括表达曲线，包括DNA修饰或突变），以及/或MIRCIRORN ARORNS ARORN ARORNANA，或包括表达概况，或使用高密度组织微阵列与新型数据挖掘工具套件相结合，定义临床上有用的肿瘤标志物，iii）在UCLA中继续进行高度专业且专注的计划，同时又具有灵活且具有成本效益临床上有用的肿瘤生物标志物。 UCLA BRL领导力具有高度强大和热情，并且非常致力于EDRN的目标。此外，加州大学洛杉矶分校（UCLA-BRL）在医学院，琼森综合癌症中心，加州大学洛杉矶分校肺癌计划和加州大学洛杉矶分校前列腺癌孢子中得到了强有力的机构支持。